Liquidia Technologies, a development-stage nanotechnology company, has closed a $16 million round of funding to accelerate development of applications related to their PRINTTM technology platform.
The Series B financing, led by New Enterprise Associates, will enable scale-up of Liquidia’s PRINTTM platform manufacturing capabilities, acceleration of preclinical testing and development in life sciences, and expansion of product development activities in specific alternative energy and materials science applications.
The financing also includes syndication from existing investors, Wakefield, Firelake Capital, and Dr. Lowry Caudill and Dr. Al Childers, founders of Magellan Labs.
Liquidia is focused on commercializing its proprietary PRINTTM (Pattern Replication In Non-wetting Templates) platform in life sciences applications that will include targeted delivery therapeutics, drug product reformulations, and drug-device combination therapies. In materials science, the company is focused initially on nano-engineered films and membranes for the alternative energy and materials science markets.
Loading...